An international, phase 3, randomized, multicenter, open- label study of Ripretinib vs Sunitinib in patients with advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and co-occurring KIT Exons 17 and/or 18 mutations who were previously treated with Imatinib (INSIGHT)

Description

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT05734105 Opens a new window